Absolute Markets Insights (AMI) reports a robust forecast for the narcolepsy therapeutics market during the 2021-2029 period. In its newly released report, AMI anticipates the market will grow owing to rapid change in lifestyle, especially in urban areas, which is leading to an increase in cases of narcolepsy around the globe.
Sodium Oxybate Accounted for the Highest Market Share in 2020.
According to Absolute Market Insights report, sodium oxybate accounted for the largest share as far as the product type segment is concerned in the global narcolepsy therapeutics market. Sodium oxybate is a potent central nervous system (CNS) depressant which has been reported to lead to drug abuse as well. It is a prescription-based drug that needs to be taken based on the recommended dosage only. The usage of the drug for purposes other than the prescribed application is considered to be illegal in numerous countries. In the U.S., for instance, individuals who take part in the risk evaluation and mitigation strategy program are prescribed sodium oxybate drug. Sodium oxybate is relatively low priced, and highly effective against narcolepsy. It can reduce daytime fatigue that leads to sleepiness, and also has the potential to bring down cases of cataplexy (short, sudden attacks of weak or paralysed muscles). The medicine, which is available in liquid form, is usually taken in a couple of doses, before sleep, and 2.5 to 4 hours after the first dose. Alcohol consumption should be avoided while consuming sodium oxybate. The drug is also called as gamma hydroxybutyrate (GHB). The rise in prescription of sodium oxybate products for the treatment of narcolepsy is a major reason for the larger share of sodium oxybate in the global narcolepsy therapeutics market.
Request for Sample Copy of This Report@ https://www.absolutemarketsinsights.com/request_sample.php?id=127
Rise in Non-Invasive Drugs Continues to Drive Growth
The condition of narcolepsy is characterized by a high degree of daytime drowsiness, coupled with cases of sudden sleep attacks. Despite the circumstances, people affected by narcolepsy find it hard to remain awake for lengthy periods. The day-time routine can be seriously disrupted as a result of this condition. Narcolepsy that is accompanied by cataplexy is referred to as type 1 narcolepsy. On the other hand, narcolepsy without cataplexy is termed as type 2 narcolepsy. Cataplexy is uncontrollable in nature, and intense emotions are often triggered as a result of the same. Narcolepsy is an incurable condition that can't be cured using medicine or surgery. However, non-invasive medications are available to help patients manage symptoms. Antidepressants, for instance, are being used for the treatment of certain symptoms of narcolepsy such as sleep paralysis, hallucinations, and loss in muscle functions. Tricyclic antidepressants (TCAs) are being used in countries like the U.S. and UK, and commonly used TCAs for narcolepsy that include imipramine and clomipramine. Selective serotonin reuptake inhibitors (SSRIs) such as femoxetine, fluoxetine and citalopram have also been recommended by the United Kingdom National Health Service as a therapeutic for narcolepsy. Therefore, the growth in the number of non-invasive treatment methods for narcolepsy is leading to the growth of the global narcolepsy therapeutics market.
Enquiry Before Buying@ https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=127
North America Produced the Highest Revenue in 2020.
Absolute Markets Insights reported that North America accounted for the highest share in the global narcolepsy therapeutics market as far as the geography is concerned. Countries such as Canada and the U.S. are seeing a rise in cases of narcolepsy. The greater awareness about narcolepsy in the U.S. and Canada, coupled with the presence of prominent market participants such as Addrenex, Arena Pharmaceuticals, Ligand Pharmaceuticals, amongst others, in North America, is a major reason for the higher share of North America in the global narcolepsy therapeutics market. Narcolepsy affects both males and females on an equal basis, and the symptoms can occur during any point. The advanced healthcare in North America helps individuals diagnose narcolepsy relatively faster. Studies show that around 1,35,000 to 2,00,000 cases are present in the U.S. alone. However, the diagnosis of narcolepsy is a difficult task. Hence, experts believe that the actual number is much higher than the reported ones. The market participants are investing heavily in the development of narcolepsy drugs with minimal side effects, especially among children. The reduction of hallucination, which often occurs during narcolepsy, is being prioritized by the healthcare industry. Therefore, the market is expected to see an influx of products that can help manage narcolepsy with ease. Change in lifestyle, and the focus on night time sleep, is being recommended by the healthcare practitioners to mitigate the effects of narcolepsy in the U.S. Delayed sleep, and drug abuse can worsen the impact of narcolepsy. Some of the primary market participants are Addrenex Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Jazz Pharmaceuticals PLC, Arena Pharmaceuticals, Inc., BIOPROJET, Shire, Ligand Pharmaceuticals, Inc., amongst others.
Request for Customization@
https://www.absolutemarketsinsights.com/request_for_customization.php?id=127
Narcolepsy Therapeutics Market:
By Product Type
- Central Nervous System Stimulants
- Sodium Oxybate
- Selective Serotonin
- Reuptake Inhibitor (SSRI)
- Tricyclic Antidepressants
- Others
By Application
- Narcolepsy With Cataplexy
- Narcolepsy Without Cataplexy
- Secondary Narcolepsy
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Get More Information@ https://www.absolutemarketsinsights.com/reports/Narcolepsy-Therapeutics-Market-2018-2026-127
About Us:
Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization. From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.
Contact Us:
Company: Absolute Markets Insights
Email id: [email protected]
Phone: +91-740-024-2424
Contact Name: Shreyas Tanna
The Work Lab,Model Colony, Shivajinagar, Pune, MH, 411016
Website: https://www.absolutemarketsinsights.com/